The cell and gene therapy field has entered a new phase of innovation, supported by technologies such as base editing, prime editing, and next-generation CRISPR systems. These tools are broadening what therapeutic developers can achieve, from precise gene correction to multiplex engineering of immune cells.
But with this expanded capability comes increased complexity. Designing an effective genome editing strategy now involves a growing set of considerations, including the selection of an appropriate editing modality, optimization of editor architecture, design of guide RNAs, and validation of performance in clinically relevant cell types. Outcomes can vary depending on genomic context, delivery method, and cell type, and decisions made early in development can have lasting consequences for downstream programs.
In this environment, traditional vendor-client relationships often fall short. Transactional service models were not designed to accommodate the iterative, adaptive nature of modern cell and gene therapy development. Instead, many teams are finding that progress is more consistent when technology providers and therapeutic developers work together as true scientific partners rather than through a purely transactional exchange.
Why traditional vendor models are becoming less effective
As genome editing technologies continue to evolve, the challenges facing therapeutic developers have grown more complex.
Selecting the right editing modality often requires comparative expertise across multiple platforms. Even after a modality is chosen, optimizing an editing strategy involves carefully balancing editing efficiency against the risk of unintended outcomes such as off-target activity and bystander edits.
Translating early proof-of-concept findings into reproducible workflows suitable for cell and gene therapy development introduces additional considerations. Results obtained in cell lines may not translate directly to primary cells, and protocols often require careful optimization before they become robust enough to support preclinical development.
Traditional vendor models struggle in this environment. Protocol handoffs without sufficient scientific context can leave teams ill-equipped to troubleshoot unexpected results. Fixed service packages may not adapt easily when programs evolve or when new technical challenges emerge.
These limitations call for a more collaborative approach, where scientific dialogue, iterative experimentation, and shared problem-solving guide development.
The competitive conflict
Another consideration for therapeutic developers is incentive alignment. Some organizations pursue internal therapeutic pipelines alongside developing genome editing platforms. While this model can drive innovation, it can also create potential conflicts of interest for external collaborators. Partners may reasonably question whether internal programs compete for resources, attention, or strategic focus.
One alternative is a model built entirely around enabling partners. Without competing therapeutic interests, technology providers can focus exclusively on supporting the success of external development programs. Because when incentives are aligned, collaboration is more straightforward. Open scientific dialogue flows more naturally, and teams can focus on solving the technical challenges of cell and gene therapy development together.
When a technology partner has no competing pipeline, partner success becomes the primary measure of value.
The value of scientific partnership
Effective partnerships create tangible advantages throughout the development lifecycle, particularly in areas where optimization and decision making are required.
Early strategy optimization: Evaluating multiple editing strategies, guide designs, or enzyme variants before committing to a single approach can help identify the most effective solution for a specific target and cell type. These early comparisons can prevent costly redesign later in development and help teams move forward with greater confidence in their chosen strategy.
Faster, smarter problem solving: Direct access to the scientists with experience in an editing platform can significantly accelerate troubleshooting and optimization. Challenges that might otherwise take months to resolve can often be addressed more efficiently through collaborative experimentation and data sharing.
Knowledge transfer that builds internal capability: Collaborative protocol development, shared data analysis, and open discussion of experimental design helps internal teams build a deeper understanding of the technology they are using, strengthening internal capabilities that inform future programs.
The ecosystem advantage
Strong partnerships also extend beyond a single technology. Access to complementary capabilities can help developers address challenges and accelerate progress across multiple stages of therapeutic development. These may include genome engineering services, screening platforms, analytical tools, and licensing pathways.
Collaborative networks can further expand this expertise. Partnerships with organizations specializing in areas such as AI-driven protein engineering or delivery technologies can provide additional resources that support program development.
Rather than functioning as isolated transactions, these relationships create an ecosystem where scientific collaboration continues to evolve alongside programs as they progress from early discovery through preclinical development and beyond.
Partnership in action: Supporting complex iPSC engineering through collaboration
A recent base editing collaboration illustrates how a partnership-based approach can accelerate complex genome editing programs. A research team with deep expertise in a disease phenotype, but limited experience in genome editing, approached Revvity to engineer a highly modified iPSC line. Together, the teams designed a strategy to introduce five precise genomic modifications, comprising four gene knockouts and one targeted knock-in within a single stem cell line.
To achieve this, each target was first individually optimized, then combined into a single-step multiplex base editing workflow alongside an automated clone selection process. This approach minimized repeated manipulation of the cells, helping preserve iPSC health and viability.
Through close collaboration and iterative optimization, the teams successfully installed all five edits in a single transfection using the Pin-point™ base editing platform, followed by clonal selection and expansion. The full engineering and scale-up process was completed in just five passages, resulting in three high-quality iPSC clones suitable for downstream validation.
This example highlights the impact of early editing strategy design and collaborative problem-solving. By aligning biological insight with genome editing expertise, the teams were able to streamline development, reduce risk, and generate complex engineered cell models efficiently. The resulting iPSC lines are now being used for further phenotypic validation, with the potential to inform new therapeutic approaches.
The future of therapeutic development is increasingly collaborative
As cell and gene therapies become more sophisticated, the gap between transactional service models and true partnership will continue to widen. Successful therapeutic programs increasingly rely on the ability to navigate complex technical decisions early in development such as choosing the right editing approach, optimizing editing strategy, and designing workflows that can scale toward clinical development.
Partnerships built on aligned incentives, transparent communication, and shared scientific objectives can help teams move more confidently through these decisions while reducing development risk.
For organizations developing genome editing therapies, the question is no longer simply whether external expertise is valuable. Instead, it is whether that expertise comes from a vendor delivering services, or from a collaborative partner that helps solve challenges to accelerate therapeutic development.
At Revvity, the focus is on enabling therapeutic developers through collaboration, technology, and scientific expertise. With no competing therapeutic pipeline, our goal is straightforward: to help partners move their programs forward.
If you are considering how a collaborative approach to base editing could accelerate your genome editing program, schedule a consultation with our scientific team to discuss your requirements in detail.
The Pin-point™ base editing platform technology is available for clinical or diagnostic study and commercialization under a commercial license from Revvity.
